Literature DB >> 25986361

Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation.

Kaija-Leena Kolho1, Katri Korpela2, Tytti Jaakkola1, Madharasi V A Pichai3, Erwin G Zoetendal4, Anne Salonen2, Willem M de Vos5.   

Abstract

OBJECTIVES: Inflammatory bowel disease (IBD) is considered to result from interplay between host and intestinal microbiota. While IBD in adults has shown to be associated with marked changes in the intestinal microbiota, there are only a few studies in children, and particularly studies focusing on therapeutic responses are lacking. Hence, this prospective study addressed the intestinal microbiota in pediatric IBD especially related to the level of inflammation.
METHODS: In total, 68 pediatric patients with IBD and 26 controls provided stool and blood samples in a tertiary care hospital and 32 received anti-tumor necrosis factor-α (anti-TNF-α). Blood inflammatory markers and fecal calprotectin levels were determined. The intestinal microbiota was characterized by phylogenetic microarray and qPCR analysis.
RESULTS: The microbiota varied along a gradient of increasing intestinal inflammation (indicated by calprotectin levels), which was associated with reduced microbial richness, abundance of butyrate producers, and relative abundance of Gram-positive bacteria (especially Clostridium clusters IV and XIVa). A significant association between microbiota composition and inflammation was indicated by a set of bacterial groups predicting the calprotectin levels (area under curve (AUC) of 0.85). During the induction of anti-TNF-α, the microbial diversity and similarity to the microbiota of controls increased in the responder group by week 6, but not in the non-responders (P<0.01; response related to calprotectin levels). The abundance of six groups of bacteria including those related to Eubacterium rectale and Bifidobacterium spp. predicted the response to anti-TNF-α medication.
CONCLUSIONS: Intestinal microbiota represents a potential biomarker for correlating the level of inflammation and therapeutic responses to be further validated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986361     DOI: 10.1038/ajg.2015.149

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  48 in total

1.  Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria.

Authors:  Chin Wen Png; Sara K Lindén; Kristen S Gilshenan; Erwin G Zoetendal; Chris S McSweeney; Lindsay I Sly; Michael A McGuckin; Timothy H J Florin
Journal:  Am J Gastroenterol       Date:  2010-07-20       Impact factor: 10.864

2.  A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.

Authors:  Kathleen Machiels; Marie Joossens; João Sabino; Vicky De Preter; Ingrid Arijs; Venessa Eeckhaut; Vera Ballet; Karolien Claes; Filip Van Immerseel; Kristin Verbeke; Marc Ferrante; Jan Verhaegen; Paul Rutgeerts; Séverine Vermeire
Journal:  Gut       Date:  2013-09-10       Impact factor: 23.059

3.  A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes.

Authors:  Ben P Willing; Johan Dicksved; Jonas Halfvarson; Anders F Andersson; Marianna Lucio; Zongli Zheng; Gunnar Järnerot; Curt Tysk; Janet K Jansson; Lars Engstrand
Journal:  Gastroenterology       Date:  2010-10-08       Impact factor: 22.682

Review 4.  Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.

Authors:  Taina Sipponen; Kaija-Leena Kolho
Journal:  Scand J Gastroenterol       Date:  2015-01       Impact factor: 2.423

5.  Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.

Authors:  Kaija-Leena Kolho; Taneli Raivio; Harry Lindahl; Erkki Savilahti
Journal:  Scand J Gastroenterol       Date:  2006-06       Impact factor: 2.423

6.  Phylogenetic analysis of dysbiosis in ulcerative colitis during remission.

Authors:  Mirjana Rajilić-Stojanović; Fergus Shanahan; Francisco Guarner; Willem M de Vos
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

7.  Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians.

Authors:  Elena Biagi; Lotta Nylund; Marco Candela; Rita Ostan; Laura Bucci; Elisa Pini; Janne Nikkïla; Daniela Monti; Reetta Satokari; Claudio Franceschi; Patrizia Brigidi; Willem De Vos
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

8.  Population-based cases control study of inflammatory bowel disease risk factors.

Authors:  Richard B Gearry; Ann K Richardson; Christopher M Frampton; Andrew J Dodgshun; Murray L Barclay
Journal:  J Gastroenterol Hepatol       Date:  2010-01-14       Impact factor: 4.029

9.  Gut microbiota signatures predict host and microbiota responses to dietary interventions in obese individuals.

Authors:  Katri Korpela; Harry J Flint; Alexandra M Johnstone; Jenni Lappi; Kaisa Poutanen; Evelyne Dewulf; Nathalie Delzenne; Willem M de Vos; Anne Salonen
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

10.  Age-dependent fecal bacterial correlation to inflammatory bowel disease for newly diagnosed untreated children.

Authors:  Felix Chinweije Nwosu; Lill-Therse Thorkildsen; Ekaterina Avershina; Petr Ricanek; Gøri Perminow; Stephan Brackmann; Morten H Vatn; Knut Rudi
Journal:  Gastroenterol Res Pract       Date:  2013-04-18       Impact factor: 2.260

View more
  68 in total

Review 1.  The role of the gut microbiome in systemic inflammatory disease.

Authors:  Jose C Clemente; Julia Manasson; Jose U Scher
Journal:  BMJ       Date:  2018-01-08

Review 2.  The Role of the Gut Microbiome in Predicting Response to Diet and the Development of Precision Nutrition Models-Part I: Overview of Current Methods.

Authors:  Riley L Hughes; Maria L Marco; James P Hughes; Nancy L Keim; Mary E Kable
Journal:  Adv Nutr       Date:  2019-11-01       Impact factor: 8.701

Review 3.  The Role of the Gut Microbiome in Predicting Response to Diet and the Development of Precision Nutrition Models. Part II: Results.

Authors:  Riley L Hughes; Mary E Kable; Maria Marco; Nancy L Keim
Journal:  Adv Nutr       Date:  2019-11-01       Impact factor: 8.701

4.  Gut microbiota alterations associated with antibody-mediated rejection after kidney transplantation.

Authors:  Junpeng Wang; Xin Li; Xiaoqiang Wu; Zhiwei Wang; Chan Zhang; Guanghui Cao; Shun Liu; Tianzhong Yan
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-24       Impact factor: 4.813

Review 5.  Gut microbiota and hematopoietic stem cell transplantation: where do we stand?

Authors:  D Zama; E Biagi; R Masetti; P Gasperini; A Prete; M Candela; P Brigidi; A Pession
Journal:  Bone Marrow Transplant       Date:  2016-06-27       Impact factor: 5.483

Review 6.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.

Authors:  Ersilia M DeFilippis; Randy Longman; Michael Harbus; Kyle Dannenberg; Ellen J Scherl
Journal:  Curr Gastroenterol Rep       Date:  2016-03

7.  Paneth cell defects in Crohn's disease patients promote dysbiosis.

Authors:  Ta-Chiang Liu; Bhaskar Gurram; Megan T Baldridge; Richard Head; Vy Lam; Chengwei Luo; Yumei Cao; Pippa Simpson; Michael Hayward; Mary L Holtz; Pavlos Bousounis; Joshua Noe; Diana Lerner; Jose Cabrera; Vincent Biank; Michael Stephens; Curtis Huttenhower; Dermot Pb McGovern; Ramnik J Xavier; Thaddeus S Stappenbeck; Nita H Salzman
Journal:  JCI Insight       Date:  2016-06-02

Review 8.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

9.  Anti-TNFα alters the natural history of experimental Crohn's disease in rats when begun early, but not late, in disease.

Authors:  Phyllissa Schmiedlin-Ren; Laura J Reingold; Christopher S Broxson; Ahren C Rittershaus; Josh S Brudi; Jeremy Adler; Scott R Owens; Ellen M Zimmermann
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-25       Impact factor: 4.052

Review 10.  Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.

Authors:  Marla Dubinsky; Jonathan Braun
Journal:  Gastroenterology       Date:  2015-08-15       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.